FDA Idvynso FDA approval has officially declared by Merck (known as MSD outside the U.S. and Canada) for its new, once-daily single-tablet regimen. This treatment, a combination of 100 mg doravirine and 0.25 mg islatravir, is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen. This landmark Idvynso FDA approval introduces the first and only non-INSTI (integrase strand transfer inhibitor), tenofovir-free, complete two-drug regimen to demonstrate non-inferior efficacy in head-to-head Phase 3 trials.
The Significance of Idvynso FDA Approval in HIV Care
The Idvynso FDA approval provides a critical alternative for patients looking to simplify their treatment without compromising efficacy. For many years, three-drug regimens including tenofovir have been the standard of care. However, as the population of people living with HIV ages, there is an increasing demand for regimens with fewer drugs and improved long-term tolerability profiles.
Clinical Trial Data Supporting Idvynso FDA Approval
The Idvynso FDA approval was based on robust data from two pivotal Phase 3 trials: Trial 052 (NCT05630755) and Trial 051 (NCT05631093). These studies evaluated the safety and efficacy of switching to the doravirine/islatravir combination compared to maintaining current antiretroviral therapy (ART).
Trial 052 Efficacy Results (Switch from Biktarvy)
| Endpoint (Week 48) | Idvynso (N=342) | Biktarvy (N=171) | Treatment Difference (95% CI) |
| HIV-1 RNA ≥50 copies/mL | 1% | 1% | 0.0% (-1.9% to 2.9%) |
| HIV-1 RNA <50 copies/mL | 92% | 94% | -1.4% (-5.5% to 2.3%) |
Trial 051 Efficacy Results (Switch from Baseline ART)
| Endpoint (Week 48) | Idvynso (N=367) | Baseline ART (N=184) | Treatment Difference (95% CI) |
| HIV-1 RNA ≥50 copies/mL | 1% | 5% | -3.8% (-7.0% to -0.6%) |
| HIV-1 RNA <50 copies/mL | 96% | 92% | 3.5% (-0.9% to 8.4%) |
AstraZeneca’s Enhertu EU Approval: Enhertu Plus Pertuzumab Cleared as First-Line Therapy for HER2-Positive Metastatic Breast Cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer, marking AstraZeneca and Daiichi Sankyo's first new EU […]
Lilly Merida Biosciences Acquisition: Eli Lilly to Pay $2.875 Billion for Precision Autoantibody Therapies
Eli Lilly will pay up to $2.875 billion to acquire Merida Biosciences, gaining a precision antibody-degradation platform led by Phase 1 candidate MER511 for Graves' […]
Roche Vabysmo PCV Study Shows Sustained Two-Year Results in Difficult-to-Treat nAMD Subtype
New two-year data from Roche's Phase IIIb/IV SALWEEN trial show that Vabysmo (faricimab) delivers durable vision gains and disease control in Asian patients with polypoidal […]
Safety and Dosing Information
Following the Idvynso FDA approval, clinicians have noted that the regimen is generally well-tolerated. Common adverse reactions reported in clinical trials included diarrhea, dizziness, fatigue, and headache. It is important to note that Idvynso is contraindicated when co-administered with strong CYP3A enzyme inducers, as they may significantly decrease the effectiveness of the medication.
